Ocular Burns
Conditions
Brief summary
The purpose of this pilot study is to explore whether corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is more effective than limbal autograft (LA) with AMLK for ocular surface reconstruction in patients with severe ocular burns.
Interventions
PROCEDUREEA and AMLK
A 7-9mm diameter corneal epithelial tissue will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
PROCEDURELA and AMLK
A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
Sponsors
Yingfeng Zheng
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Unilateral severe ocular burns with more than half limbal stem cells deficiency (LSCD). The history of the disease is at least 12 months at the time of screening visit. 2. Presence of superficial neo-vascularization affecting at least 2 cornea quadrants and involving central cornea. 3. Informed consent signed by a patient or legal guardian, or having the ability to comply with study assessments for the full duration of the study.
Exclusion criteria
1. LSCD of mild degree, with less than 2 quadrants of neo-vessel invasion and without central cornea involvement. 2. LSCD by ocular surface disorders other than ocular burns. 3. Eyelids malposition. 4. The center corneal thickness\<450µm, the depth of corneal opacity\<150µm or the full corneal lamellar opacity. 5. High myopia with a spherical equivalent of -15.0 D or less. 6. Corneal or ocular surface infection within 30 days prior to study entry. 7. Ocular surface malignancy. 8. Uncontrolled diabetes with most recent HgA1c greater than 8.5%. 9. Renal failure with creatinine clearance ≤ 25mL/min per 1.73 m2. 10. Alanine aminotransferase \> 40IU/L, or aspartate aminotransferase \> 40IU/L. 11. Platelet levels \< 150,000 or \> 450,000 per microliter. 12. Hemoglobin \< 12.0 g/dL (male) or \< 11.0 g/dL (female); 13. Prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; An international normalized ratio greater than 3 in patients accepting anticoagulant therapy. 14. Pregnancy (positive test) or lactation. 15. Participation in another simultaneous medical investigation or clinical trial. 16. Severe cicatricial eye disease; Conjunctival scarring with fornix shortening. 17. Ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases. 18. Severe dry eye disease as determined by Schirmer's test \< 2mm at least in one eye. 19. Any medical or social condition that in the judgment of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent. 20. Signs of current infection, including fever and treatment with antibiotics. 21. Active immunological diseases. 22. History of anti-glaucoma surgeries.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Success rate of corneal reepithelialization in disease eyes. | 12 months | The percentage of patients with completely epithelized and avascular corneal surface in disease eyes. |
Countries
China
Outcome results
None listed